KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) EBT (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of EBT data on record, last reported at $1.3 billion in Q4 2025.

  • For Q4 2025, EBT rose 17.11% year-over-year to $1.3 billion; the TTM value through Dec 2025 reached $4.6 billion, up 1768.49%, while the annual FY2025 figure was $4.6 billion, 1768.49% up from the prior year.
  • EBT reached $1.3 billion in Q4 2025 per VRTX's latest filing, up from $1.3 billion in the prior quarter.
  • Across five years, EBT topped out at $1.3 billion in Q4 2025 and bottomed at -$3.4 billion in Q2 2024.
  • Average EBT over 5 years is $811.7 million, with a median of $1.1 billion recorded in 2021.
  • Peak YoY movement for EBT: surged 2417.65% in 2022, then crashed 391.97% in 2024.
  • A 5-year view of EBT shows it stood at $870.9 million in 2021, then grew by 23.64% to $1.1 billion in 2022, then grew by 6.58% to $1.1 billion in 2023, then fell by 0.97% to $1.1 billion in 2024, then grew by 17.11% to $1.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were $1.3 billion in Q4 2025, $1.3 billion in Q3 2025, and $1.3 billion in Q2 2025.